Lexicon’s Zynquista: Negative Adcomm Vote In Type 1 Diabetes Includes Support For Revised Indication

Some panelists favored use in T1D patients with mild chronic kidney disease, even though that was not the original indication Lexicon proposed, which was rejected in an 11-3 vote.

Risk benefit
Lexicon's sotagliflozin in type 1 diabetes patients with chronic kidney disease failed the adcomm's risk-benefit test. (Shutterstock)

More from US Advisory Committees

More from Geography